The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.
Age: Patients must be > 1 year of age and . 30 years of age at time of initiation of protocol therapy.
Diagnosis: Patients have a histologically or radiographically confirmed relapsed or refractory STS.
Disease Status: Patients must have evaluable disease.
Performance Level: Karnofsky . 50% for patients > 16 years old, and Lansky . 50 for patients 1-16 years old. (See Appendix I)
Significant organ dysfunction, not meeting inclusion criteria.
Pediatric subjects who are considered wards of some entity.
Pregnancy or Breast-Feeding Pregnant or breast-feeding woman will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies.
Growth factor: Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days.
Single group
Pazopanib
DrugGiven by mouth
Trabectedin
DrugGiven by IV
Ipilimumab
DrugGiven by IV
Nivolumab
DrugGiven by IV
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
